ArticleJournal of toxicology2026
In Vitro hRPTEC TERT1 Model for Uranium-Induced Nephrotoxicity Pathway Study.
Article in Journal of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In Vitro hRPTEC TERT1 Model for Uranium-Induced Nephrotoxicity Pathway Study.Journal of toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a heavy metal and alpha emitter, uranium U(VI) presents chemical and radiological toxicity risks. Its toxicity particularly targets the kidneys in the event of intoxication, but the detailed study mechanisms leading to uranium-induced renal failure have not yet been studied based on the adverse outcome pathway (AOP) approach. Using a well-specialized in vitro model of renal proximal tubule epithelial cells (hRPTEC TERT1), this research aims to contribute to the development of the AOP of kidney toxicity. After identifying the U(VI) concentrations that induce deleterious effects (apoptosis and necrosis/cytotoxicity), key events linked to oxidative stress, apoptosis, survival, inflammation, and kidney toxicity are studied at the gene and protein levels. Apoptosis (Caspase 3/7 activity) is induced starting from exposure to 300 μM and necrosis (LDH assay) from 500 μM with a rate of 60%. hRPTEC cells have an IC50 of 420 μM after 48 h U(VI) exposure. Uranium induces an early 2-fold rise in ROS production, and an antioxidant response was observed accordingly. Cell survival signaling appeared to be enhanced at 100 μM, while higher concentrations (> 300 μM) induced a marked inflammatory response, with increased levels of TNFα (6,5-fold), IL-6, and IL-18, leading to a 16% increase in caspase 3/7 at 300 μM and LDH at 500 μM. A slight increase of 22% in the KIM-1 protein level is observed at 500 μM, and limited changes occurred for other nephrotoxicity biomarkers. In conclusion, this exploratory work generated a multiplex panel detailing the key events in the AOP of uranium-induced renal failure (Graphical Abstract). This panel features a human phenotype of renal proximal tubule epithelial cells, the preferential target of uranium in the kidney, while also considering the dose-dependent effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.